Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who had well-defined taxane resistance
about
Efficacy and safety of eribulin in taxane-refractory patients in the 'real world'.Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer: a post-marketing observational study.Incidence and relative risk of peripheral neuropathy in cancer patients treated with eribulin: a meta-analysis.Bi-weekly eribulin therapy for metastatic breast cancer: a multicenter phase II prospective study (JUST-STUDY).Induction therapy with paclitaxel and bevacizumab followed by switch maintenance therapy with eribulin in Japanese patients with HER2-negative metastatic breast cancer: a multicenter, collaborative, open-label, phase II clinical study for the SBCCSG
P2860
Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who had well-defined taxane resistance
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Phase II clinical study of eri ...... well-defined taxane resistance
@en
type
label
Phase II clinical study of eri ...... well-defined taxane resistance
@en
prefLabel
Phase II clinical study of eri ...... well-defined taxane resistance
@en
P2093
P2860
P1476
Phase II clinical study of eri ...... well-defined taxane resistance
@en
P2093
Hirofumi Yamada
Katsuhiko Okubo
Kazuo Ishizuna
Kei Kimizuka
Masafumi Kurosumi
Satoshi Hata
Takashi Sakurai
Toshihiro Kai
Tsuyoshi Saito
P2860
P2888
P304
P356
10.1007/S10549-016-3808-X
P407
P577
2016-04-28T00:00:00Z